List view / Grid view
24 August 2023 | By Bio-Rad Laboratories Inc.
Watch our industry experts to learn about the tangible benefits and best practice of custom flow cytometry automation projects. You’ll discover how to reduce your challenges implementing tailored automation, controlling the quality of the data produced and improving the reliability of your data acquisition.
Researchers from the German Cancer Research Center (DKFZ) and the Cambridge Stem Cell Institute have developed an artificial intelligence (AI) system capable of identifying and characterising white and red blood cells within microscopic images of blood samples. This AI algorithm holds the potential to aid medical professionals in diagnosing blood…
La Jolla biologists harness machine learning and computational tools to make sense of immune system data.
Tune in to this episode to hear experts discussing the hot topic that is AI and how AI technology is used in drug discovery, looking specifically at how Biotechs & Pharma are trying to keep up with emerging technology.
Machine learning (ML) presents a promising opportunity to revolutionize early cancer detection in primary care, addressing the challenges associated with diagnostic errors and improving patient outcomes. The potential of ML in this field is highlighted in a recent paper published in Oncoscience
This article is the second part of Drug Target Review’s Izzy Wood’s discussion with Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, exploring the role of AI in target discovery, its applications in personalised medicine, and the evolving landscape of pharmaceutical development.
In this interview Drug Target Review’s Izzy Wood and Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, uncover the untapped potential of AI in target discovery. Alchemab’s revolutionary platform aims to identify common antibodies in resilient individuals and uncover the antigens that contribute to their disease-fighting…
A new Drug Target Review issue is now ready to download! This issue features articles on cell and gene therapy, imaging and screening.
The decisions you make about your biologics candidates early in the pipeline ultimately affect their success as therapeutics. Combine sizing and stability information to develop successful biologics.
Researchers from the University of Illinois have identified a new class of ribosomally synthesised and post-translationally modified peptides (RiPPs) named "daptides" that have haemolytic activity.
In this article, Drug Target Review's Ria Kakkad and Izzy Wood explore the results of the latest research on lab automation techniques and technologies designed to accelerate drug discovery.
A new Drug Target Review is now ready to download! This issue features articles which explore antibodies, vaccines and assays.
Tune into this podcast to hear experts discussing scaling up 3D organoids!
An AI strategy developed by US scientists could accelerate the development of new antibody drugs.
Technology is infamous for falling into a hype cycle, with its peaks and valleys of exaggerated expectations and disillusionment — AI-driven drug discovery is no exception. In this article, Aaron Daugherty, Vice President Discovery at Aria Pharmaceuticals, highlights how the industry can use AI to transform research.
